Spyglass Pharma earnings were N/A for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. The latest SGP earnings report on Sep 30, 2025 announced Q3 2025 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SGP reported annual earnings of -$29.2M, with 119% growth.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.